Navigation Links
Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
Date:5/29/2012

ed patients and as an oral formulation to treat HE in patients with chronic liver cirrhosis. Ocera has completed studies in healthy volunteers and cirrhotic patients and phase 2 studies are ongoing. For more information: www.Clinicaltrials.gov (OCR-002)

About Hepatic Encephalopathy (HE)
HE is an often reversible neuropsychiatric complication observed in patients with acute liver failure or chronic liver cirrhosis in whom the metabolic conversion of ammonia to urea in the liver fails.  With severe liver impairment, toxic substances that are normally removed by the liver such as ammonia accumulate in the blood.  Elevated ammonia levels can impair the function of brain cells, cause cerebral edema and may elevate intracranial pressure. Signs and symptoms of HE include impaired cognition, confusion and a decreased level of consciousness, which can progress to coma and ultimately death. 


'/>"/>
SOURCE Ocera Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
2. Cardinal Health Statement in Response to Preliminary Injunction Hearing February 29, 2012
3. Vermillion to Report Preliminary Results for Fourth Quarter and Fiscal Year 2011 on February 23, 2012
4. Watson Confirms Court Stays Preliminary Injunction
5. Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
6. Hill-Rom Announces Preliminary Fiscal First Quarter Financial Results; Updates 2012 Financial Outlook
7. Volcano Corporation Announces Preliminary Fourth Quarter 2011 Revenues
8. CareFusion Announces Preliminary Second Quarter Results
9. Sanofi Announces Court Ruling Granting Preliminary Injunction Against Synvisc-One® Competitor Product
10. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
11. PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, ... to treat infectious disease, today announced it has ... studies of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin ... and data from these studies support the safety ... (IV) at the intended therapeutic dose. The conclusion ...
(Date:9/22/2014)... and SHANGHAI , Sept. 22, ... a global knowledge leader in healthcare technology, media ... support healthcare innovation in China ... health technologies. Continua and BHG announced this new ... held this week in Washington, DC ...
(Date:9/22/2014)...  Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer ... disease, cancer and other life-threatening conditions, disclosed today ... has informed the Company that it plans to ... of a five-year $5.9 million contract that was ... DARPA,s Dialysis-Like Therapeutics (DLT) program. The ...
Breaking Medicine Technology:Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
... 14, 2011 Reportlinker.com announces that a new ... Smart Infusion Pumps ... one of the most common therapeutic procedures that ... receive. Yet the lack of standardization among the ...
... Bend Research Inc. ( www.bendresearch.com ), a leading independent ... has entered into a licensing agreement with Merck, through ... the agreement, Bend Research will provide Merck access to ... additional needs, Bend may also provide Merck with access ...
Cached Medicine Technology:Smart Infusion Pumps 2Smart Infusion Pumps 3Bend Research Signs Technology Licensing Agreement with Merck 2
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... PA (PRWEB) September 22, 2014 An ... for patients to the problem of side-sleeping. "My lower ... side, so I designed a solution to this problem," ... asleep comfortably than to have your arm 'fall asleep.'" ... on his or her side more comfortably. It avoids ...
(Date:9/22/2014)... West Orange, NJ. September 22, 2014. Kessler researchers ... of a 10-week psychoeducational wellness program in people ... in mood, overall mental health, perceived stress, and ... wellness group for individuals living with MS: Description ... September 3 in the International Journal of ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
(Date:9/22/2014)... 2014 Pain does not need to rule ... user- and reader-friendly book designed to guide the individual who ... This inspirational book is written to help the reader who ... way to regain a pain-free life — a daily “go-to” ... , Chronic pain has become an epidemic, with over 100 ...
Breaking Medicine News(10 mins):Health News:Looking ahead: Whole eye transplant under development 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2
... Francisco's 2002 Gay Pride, San Francisco Department of Public Health ... ,In the above said campaign, a cartoon penis by ... hundreds of homo whores who had gathered there to get ... were not happy with the Ad and scoffed at the ...
... habits, is easily acquired but quite difficult to stop.// All ... or at least have to try out recommended smoking cessation ... the ages of 16 and 24 years do try to ... try out tested methods. ,An article presented in ...
... A US company claimed to have developed a weight reduction ... also could cut the risk of heart disease, diabetes and ... five to 10 percent when taken for a year. ... developed by Californian biopharmaceutical firm Orexigen for 48 weeks lost ...
... apple and plum, now strawberry wine will add variety from ... the Horticulture Produce Marketing Corp's (HPMC) juice and wine processing ... ,The new wine was produced after year-long research by experts ... town Kalpa in Kinnaur district, which produces some of the ...
... Systemic sclerosis (SSc) is a chronic autoimmune disorder ... tissue fibrosis.// More than skin deep, this thickening ... capillaries, the gastrointestinal tract, the lungs, and the ... organ dysfunction, serious illness, and death. Researchers have ...
... better safety for patients in ICU by adhering to ... threatening// catheter-related infections. ICUs can become thoroughly aseptic by ... syringes and catheters. A detailed report was made by ... of the report are published in New England Journal ...
Cached Medicine News:Health News:Tried To Quit Smoking And Failed? Call 1-800-QUIT-NOW 2Health News:New Treatment Offers Hope for Systemic Sclerosis 2Health News:Simple Steps to Safe Guard Patients from Bloodstream Infections in ICU 2
... and high power negative lens delivering magnification ... benefit of this system is ease of ... made possible due to a superior depth ... and individual interpupillary adjustment provides stability for ...
... represents a breakthrough for patients experiencing degenerative ... system gathers bone during decompression, bone bed ... into the implant's chamber produces a local ... the iliac crest. The BAK/C implant is ...
Inside and out, the Achieva is designed to unleash a new era, in which the clinical capabilities of MR will further expand....
Signa Profile is built on the Signa foundation to deliver speed & image quality....
Medicine Products: